{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:06:36Z","timestamp":1777529196868,"version":"3.51.4"},"reference-count":0,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Background.<\/jats:bold> Fibulin-3 is a new potential biomarker for malignant mesothelioma (MM). This study evaluated the potential applicability of fibulin-3 plasma levels as a biomarker of response to treatment and its prognostic value for progressive disease within 18 months. The potential applicability of fibulin-3 in comparison with or in addition to soluble mesothelin-related peptides (SMRP) was also assessed.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Patients and methods.<\/jats:bold> The study included 78 MM patients treated at the Institute of Oncology Ljubljana between 2007 and 2011. Fibulin-3 levels in plasma samples obtained before treatment and in various responses to treatment were measured with the enzyme-linked immunosorbent assay.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results.<\/jats:bold> In patients evaluated before the treatment, fibulin-3 levels were not influenced by histopathological sub-types, tumour stages or the presence of metastatic disease. Significantly higher fibulin-3 levels were found in progressive disease as compared to the levels before treatment (Mann-Whitney [U] test = 472.50, p = 0.003), in complete response to treatment (U = 42.00, p = 0.010), and in stable disease (U = 542.00, p = 0.001). Patients with fibulin-3 levels exceeding 34.25 ng\/ml before treatment had more than four times higher probability for developing progressive disease within 18 months (odds ratio [OR] = 4.35, 95% confidence interval [CI] 1.56\u201312.13). Additionally, patients with fibulin-3 levels above 34.25 ng\/ml after treatment with complete response or stable disease had increased odds for progressive disease within 18 months (OR = 6.94, 95% CI 0.99\u201348.55 and OR = 4.39, 95% CI 1.63\u201311.81, respectively).<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusions.<\/jats:bold> Our findings suggest that in addition to SMRP fibulin-3 could also be helpful in detecting the progression of MM.<\/jats:p>","DOI":"10.1515\/raon-2015-0019","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T13:41:48Z","timestamp":1435758108000},"page":"279-285","source":"Crossref","is-referenced-by-count":20,"title":["Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma"],"prefix":"10.1515","volume":"49","author":[{"given":"Viljem","family":"Kovac","sequence":"first","affiliation":[{"name":"Institute of Oncology Ljubljana, Zalo\u0161ka cesta 2, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metoda","family":"Dodic-Fikfak","sequence":"additional","affiliation":[{"name":"Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niko","family":"Arneric","sequence":"additional","affiliation":[{"name":"Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vita","family":"Dolzan","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alenka","family":"Franko","sequence":"additional","affiliation":[{"name":"Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2015,8,21]]},"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/raon\/49\/3\/article-p279.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/raon-2015-0019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T06:28:17Z","timestamp":1617776897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/raon-2015-0019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,21]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,8,21]]},"published-print":{"date-parts":[[2015,9,1]]}},"alternative-id":["10.1515\/raon-2015-0019"],"URL":"https:\/\/doi.org\/10.1515\/raon-2015-0019","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,21]]}}}